Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia (PAPALDO)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2015 by Jules Bordet Institute
Information provided by (Responsible Party):
Jules Bordet Institute Identifier:
First received: July 27, 2012
Last updated: January 5, 2015
Last verified: January 2015
The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile neutropenia among patients with breast cancer, treated with chemotherapy and presenting with a low to moderate risk of developing febrile neutropenia.

Condition Intervention Phase
Breast Cancer
Drug: GCSF administration on days 8 and 12 after chemotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia

Resource links provided by NLM:

Further study details as provided by Jules Bordet Institute:

Primary Outcome Measures:
  • Occurrence of a febrile neutropenic episode defined as fever (>=38.5°C once or >=38°C twice within 12 hours interval) and neutropenia (ANC < 0.5 IU) [ Time Frame: At the beginning of 2nd chemotherapy cycle, no more than 30 days after randomization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Need for unplanned hospitalization [ Time Frame: At the beginning of second chemotherapy cycle, no more than 30 days after randomization ] [ Designated as safety issue: Yes ]
    Unplanned hospitalization is defined as the need to admit a patient outside of the schedule that was planned for chemotherapy administration

  • Complicated febrile neutropenic episode [ Time Frame: At the beginning of the second chemotherapy cycle, no more than 30 days after randomization ] [ Designated as safety issue: No ]
    A complicated febrile neutropenic episode is defined as a febrile neutropenic episode (see above) that does not resolve without the occurrence of serious medical complication as defined in Klasterky J et al; JCO 2000 : 3038-3051

  • Mortality any cause [ Time Frame: 30 days from randomization ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 142
Study Start Date: July 2012
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Subcutaneous GCSF 5 µg/kg days 8 and 12
Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
Drug: GCSF administration on days 8 and 12 after chemotherapy
No Intervention: No intervention


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Breast cancer Chemotherapy administration (new line) Chemotherapy type : FEC, EC, AC, docetaxel containing regimen Chemotherapy setting : adjuvant or neoadjuvant

Exclusion Criteria:

Eligibility to receive reimbursed GCSF

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01658956

Institut Jules Bordet Recruiting
Brussels, Belgium, 1000
Contact: Aspasia Georgala, MD    3225413255   
Contact: Marianne Paesmans    3225413399   
Principal Investigator: Aspasia Georgala, MD         
Sponsors and Collaborators
Jules Bordet Institute
  More Information

Responsible Party: Jules Bordet Institute Identifier: NCT01658956     History of Changes
Other Study ID Numbers: Institut Jules Bordet 
Study First Received: July 27, 2012
Last Updated: January 5, 2015
Health Authority: Belgium: Ethics Committee

Keywords provided by Jules Bordet Institute:
Breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Febrile Neutropenia
Neoplasms by Site
Breast Diseases
Skin Diseases
Leukocyte Disorders
Hematologic Diseases processed this record on October 21, 2016